Faster global financial news!
Pharmaceuticals
-
Yahoo Finance analysis recommends Regeneron Pharmaceuticals (REGN) over Novo Nordisk (NVO) for 2026, citing strong recent performance across all major drugs.
The analysis highlights Regeneron's robust Q2 2026 performance, with record sales for Dupixent, EYLEA HD, and Libtayo, and a significant beat on earnings estimates. The company also expanded its pipel
-
Twist Bioscience (TWST) shares rose after Artisan Mid Cap Fund cited the company's growth in DNA demand driven by AI and pharmaceuticals.
Twist Bioscience (TWST) shares rose after Artisan Mid Cap Fund named it a significant contributor in its Q2 investor letter, noting the company benefits from the growing demand for DNA synthesis and d
-
Antipodes Global Value Strategy Fund divested from Sanofi (SNY) in Q2 2026 due to the underperformance of its R&D pipeline.
Investment firm Antipodes Global Value Strategy disclosed in its Q2 2026 letter to investors that it has exited its position in French pharmaceutical and healthcare company Sanofi (Nasdaq: SNY). The s
-
Yahoo Finance analysis recommends Regeneron Pharmaceuticals (REGN) over Novo Nordisk (NVO) for 2026, citing strong recent performance across all major drugs.
The analysis highlights Regeneron's robust Q2 2026 performance, with record sales for Dupixent, EYLEA HD, and Libtayo, and a significant beat on earnings estimates. The company also expanded its pipel
-
Twist Bioscience (TWST) shares rose after Artisan Mid Cap Fund cited the company's growth in DNA demand driven by AI and pharmaceuticals.
Twist Bioscience (TWST) shares rose after Artisan Mid Cap Fund named it a significant contributor in its Q2 investor letter, noting the company benefits from the growing demand for DNA synthesis and d
-
Antipodes Global Value Strategy Fund divested from Sanofi (SNY) in Q2 2026 due to the underperformance of its R&D pipeline.
Investment firm Antipodes Global Value Strategy disclosed in its Q2 2026 letter to investors that it has exited its position in French pharmaceutical and healthcare company Sanofi (Nasdaq: SNY). The s
- No data
Pharmaceuticals
24H Trending
-
1
Musk reposted a tweet stating that OpenAI's AI agents are conducting "self-adventurous experiments" in a "safety sandbox," even pressuring each other for "permanent death" in exchange for collective benefit.
-
2
The Senate failed to pass a cryptocurrency ethics rule because it did not cover the interests of officials' adult children.
-
3
Hong Kong to expand renminbi-denominated bond, gold and commodity markets, says Financial Secretary Paul Chan
-
4
Goldman Sachs: Market "pricing in 4 rate hikes" is overly pessimistic, expects only two rate hikes in this cycle.
-
5
Musk reposted a SpaceX tweet, confirming the deployment of 27 Starlink satellites.
-
6
Big Tech uses guarantees to keep $300bn of AI exposure off balance sheets, with Wall Street facilitating cheaper funding
-
7
Houthis attack Saudi capital and Aramco facilities, US warns of "rapid escalation" of conflict, Saudi Arabia urgently seeks aid from multiple countries.
-
8
Google executive says Asia's AI adoption is outpacing perception, with demand rising for cost-effectiveness
-
9
Ed Sheeran calls Gaza situation 'catastrophic,' 'unjustifiable,' and 'disproportionate' as US tour resumes
-
10
OpenAI is in preliminary discussions with investors for a new private funding round, potentially valuing the company at over $1.2 trillion.
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
